PUBLISHER: Grand View Research | PRODUCT CODE: 1362918
PUBLISHER: Grand View Research | PRODUCT CODE: 1362918
U.S. Specialty Injectable Generics Market Size, Share & Trends Analysis Report By Type (Drugs, Biologics), By Application (Oncology, CNS, Cardiovascular), By Distribution Channel (Hospitals, Retail Pharmacy), And Segment Forecasts, 2023 - 2030
U.S. Specialty Injectable Generics Market Growth & Trends:
The U.S. specialty injectable generics market is expected to reach USD 36.16 million by 2030, expanding at a CAGR of 8.33% from 2023 to 2030, according to a new report by Grand View Research, Inc.. High presence of key pharmaceutical players in the U.S. and the rising prevalence of chronic diseases are among the key drivers for the growth. Furthermore, the growing number of FDA approvals for specialty injectable generics, emerging research & development activities, and well-established healthcare infrastructure contribute to U.S. space growth.
In the U.S., the increasing cancer diagnosis and treatment demand has created immense demand for specialty injectable generics. According to the American Cancer Society, in 2022, it is expected that 1.9 million new oncology cases are anticipated to diagnose and 609,360 cancer deaths in the U.S. This factor has led companies to increase their focus on the development of innovative and effective treatments for oncology cases. For instance, in November 2022, Amneal Pharmaceuticals, Inc. received abbreviated new drug application approval from the U.S. FDA for leuprolide acetate. The injection is used for advanced prostatic cancer treatment.
Furthermore, pharmaceutical drug products have become increasingly important as they provide consumers with an array of treatments and life expectancy-enhancing patient lives. Thereby, continued specialty injectable generics innovation has benefited the U.S. space. For instance, in June 2022, Dr. Reddy's Laboratories Ltd. acquired branded & generic injectable products portfolio from Eton Pharmaceuticals, Inc. The acquisition will support Dr. Reddy's company to expand & accelerate affordable medications for patients. The acquisition will add Dr. Reddy's U.S. institutional business with limited competition injectable products.
Likewise, the COVID-19 pandemic has moderately impacted the specialty injectable generics market. During the pandemic, there was a rapid demand for specialty injections. However, shortage of production and products, and supply chain disruptions in hospitals, retail pharmacy had hampered the supply chain to some extent. One of the key issues faced by companies was production demand and delivery of products to end users. However, post-pandemic the market has witnessed rapid growth with increased production and supply chain.
Furthermore, the key participants are engaged in strategies such as partnerships, agreements, mergers & acquisitions, collaborations, and launches, among others, to expand their global footprints and portfolios. For instance, in January 2023, Glenmark Pharmaceuticals Inc., USA launched Bumetanide Injection USP, 1 mg/4 mL Single-Dose Vials & 2.5 mg/10 Multi-Dose Vials which is Validus Pharmaceuticals, Inc's generic version of Bumex1 Injection, 0.25 mg/mL. Similarly, in October 2022, Akorn Operating Company LLC launched the generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference, California.
U.S. Specialty Injectable Generics Market Report Highlights:
- Based on type, the Biologics segment held the largest revenue share in 2022 and is anticipated to grow at the fastest growth rate over the forecast period owing to the wide adoption of the biologics in the treatment of chronic diseases
- The oncology segment dominated the U.S. market with a revenue share of 48.9% in 2022. The growth is attributed to the growing burden of cancer cases and strong demand for breast and lung cancer therapies, among other types.
- On the basis of distribution channels, the hospital pharmacy segment dominated the U.S. market in 2022 due to the presence of hospital pharmacies and increased injectable demand among critical patients.
- Key players operating in the space are constantly focusing on product launches and geographical expansion to maintain their presence.
- A few of the key players include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Baxter International, Novartis AG, Fresenius SE & Co. KGaA, Par Pharmaceutical, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Sagent Pharmaceuticals, Inc., Mylan N.V.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Segment 1
- 1.2.2. Segment 2
- 1.2.3. Segment 3
- 1.3. Research Methodology
- 1.3.1. Information Analysis
- 1.3.2. Market Formulation & Data Visualization
- 1.3.3. Data Validation & Publishing
- 1.4. Research Assumptions
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Global Market: CAGR Calculation
- 1.10. Objective
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Emerging chronic diseases patients
- 3.2.1.2. Increasing number of new FDA injectable generics drugs approvals
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of injectable
- 3.2.1. Market Driver Analysis
- 3.3. SWOT Analysis, by Factor
- 3.4. Industry Analysis- Porter's
- 3.5. Consumer Behavior Analysis
- 3.6. Target Disease Population
- 3.7. Regulatory Scenario
- 3.8. Reimbursement Scenario
- 3.9. Unmet Needs and Opportunity Analysis
- 3.10. KOL Responses
Chapter 4. Type Business Analysis
- 4.1. U.S. Specialty Injectable Generics Market: Type Movement Analysis
- 4.2. Drugs
- 4.2.1. Drugs Market, 2018 - 2030 (USD Million)
- 4.3. Biologics
- 4.3.1. Biologics Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. U.S. Specialty Injectable Generics Market: Application Movement Analysis
- 5.2. Oncology
- 5.2.1. Oncology Market, 2018 - 2030 (USD Million)
- 5.3. Cardiovascular
- 5.3.1. Cardiovascular Market, 2018 - 2030 (USD Million)
- 5.4. CNS
- 5.4.1. CNS Market, 2018 - 2030 (USD Million)
- 5.5. Infectious Diseases
- 5.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
- 5.6. Autoimmune Disorders
- 5.6.1. Autoimmune Disorders Market, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
- 6.1. U.S. Specialty Injectable Generics Market: Distribution Channel Movement Analysis
- 6.2. Hospital
- 6.2.1. Hospital Market, 2018 - 2030 (USD Million)
- 6.3. Retail Pharmacy
- 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
- 6.4. Others
- 6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company Categorization
- 7.2. Strategy Mapping
- 7.3. Company Market Share Analysis, 2022
- 7.4. Company Profiles/Listing
- 7.4.1. Pfizer, Inc.
- 7.4.1.1. Overview
- 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Strategic Initiatives
- 7.4.2. Teva Pharmaceutical Industries Ltd.
- 7.4.2.1. Overview
- 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Strategic Initiatives
- 7.4.3. Baxter International
- 7.4.3.1. Overview
- 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Strategic Initiatives
- 7.4.4. Novartis AG
- 7.4.4.1. Overview
- 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Strategic Initiatives
- 7.4.5. Fresenius SE & Co. KGaA
- 7.4.5.1. Overview
- 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Strategic Initiatives
- 7.4.6. Par Pharmaceutical
- 7.4.6.1. Overview
- 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Strategic Initiatives
- 7.4.7. Hikma Pharmaceuticals PLC
- 7.4.7.1. Overview
- 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Strategic Initiatives
- 7.4.8. Dr. Reddy's Laboratories
- 7.4.8.1. Overview
- 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Strategic Initiatives
- 7.4.9. Sagent Pharmaceuticals, Inc.
- 7.4.9.1. Overview
- 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.9.3. Product Benchmarking
- 7.4.9.4. Strategic Initiatives
- 7.4.10. Mylan N.V.
- 7.4.10.1. Overview
- 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.4.10.3. Product Benchmarking
- 7.4.10.4. Strategic Initiatives
- 7.4.1. Pfizer, Inc.
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 U.S. Specialty Injectable Generics market revenue estimated and forecast, by type, 2018 - 2030 (USD million)
- Table 4 U.S. Specialty Injectable Generics market revenue estimated and forecast, by application, 2018 - 2030 (USD million)
- Table 5 U.S. Specialty Injectable Generics market revenue estimated and forecast, by distribution channel, 2018 - 2030 (USD million)
- Table 6 Company market share, 2022
List of Figures
- Fig. 1 Market Research Process
- Fig. 2 Information Procurement
- Fig. 3 Primary Research Pattern
- Fig. 4 Market Research Approaches
- Fig. 5 Value Chain-Based Sizing & Forecasting
- Fig. 6 Market Formulation & Validation
- Fig. 7 U.S. Specialty Injectable Generics Market Segmentation
- Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 11 Penetration & Growth Prospect Mapping
- Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- Fig. 13 Porter's Five Forces Analysis
- Fig. 14 U.S. Specialty Injectable Generics market: Type outlook and key takeaways
- Fig. 15 U.S. Specialty Injectable Generics market: Type movement analysis & market share 2022 & 2030
- Fig. 16 Drugs market, 2018 - 2030 (USD Million)
- Fig. 17 Biologics market, 2018 - 2030 (USD Million)
- Fig. 18 U.S. Specialty Injectable Generics market: Application outlook and key takeaways
- Fig. 19 U.S. Specialty Injectable Generics market: Application movement analysis & market share 2022 & 2030
- Fig. 20 Oncology market, 2018 - 2030 (USD Million)
- Fig. 21 Cardiovascular market, 2018 - 2030 (USD Million)
- Fig. 22 CNS market, 2018 - 2030 (USD Million)
- Fig. 23 Infectious Diseases market, 2018 - 2030 (USD Million)
- Fig. 24 Autoimmune Disorders market, 2018 - 2030 (USD Million)
- Fig. 25 Others market, 2018 - 2030 (USD Million)
- Fig. 26 U.S. Specialty Injectable Generics market: Distribution channel outlook and key takeaways
- Fig. 27 U.S. Specialty Injectable Generics market: Distribution channel movement analysis & market share 2022 & 2030
- Fig. 28 Hospital market, 2018 - 2030 (USD Million)
- Fig. 29 Retail pharmacy market, 2018 - 2030 (USD Million)
- Fig. 30 Others market, 2018 - 2030 (USD Million)
- Fig. 31 Strategy Mapping
